Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome
The Journal of Clinical Endocrinology & Metabolism · 16.10.2025 · 110 (11) · e3794-e3802
DOI: 10.1210/clinem/dgaf114 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.02.2025. Verfasst von Henrik Elenius und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethe…. Hauptthemen laut MEDLINE: Dihydroxyphenylalanine, ACTH Syndrome, Ectopic, Organometallic Compounds, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH, The National Institute of Diabetes, and Digestive and Kidney Diseases, National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Context
Identification of tumors causing ectopic ACTH syndrome (EAS) is challenging. 68Ga-DOTATATE (DOTA) and 18F-DOPA (DOPA) positron emission tomography/computed tomography (PET/CT) scans are promising imaging modalities warranting further evaluation.
Objective
This work aimed to compare DOTA and DOPA PET/CT performance in detecting ectopic sources of adrenocorticotropin (ACTH).
Methods
A prospective comparison of DOTA, DOPA, and conventional imaging modalities in EAS was conducted at a tertiary referral center. Participants included 24 patients with EAS from neuroendocrine tumors confirmed by pathology and/or biochemical cure. Interventions included DOTA PET/CT, DOPA PET/CT, CT, MRI, gated cardiac CT/MRI, and Octreoscan (OCT) performed between 2014 and 2024. Main outcome measures included sensitivity (Se) and positive predictive value (PPV) for each imaging modality, and 7 combinations thereof, in patients with identified tumors.
Results
Of functional scans, Se for DOPA was higher than OCT (Se 88%; 95% CI, 67%-97% vs 31%; 95% CI, 10%-61%) and overlapped DOTA (Se 79%; 95% CI, 57%-92%). Among structural modalities, CT had the highest Se (96%; 95% CI, 76%-100%) when interpreted knowing results of functional scans; Se was 57% (95% CI, 35%-76%) without those data. Cardiac CT/MRI had the highest PPV (100% for each). Combinations of CT/MRI plus DOTA and/or DOPA provided high PPVs (89%-100%) with Se 64% to 87%; all CIs overlapped. Combined CT and MRI without functional scans provided PPV 79% with Se 55%, although CI overlapped with combinations that included DOTA/DOPA.
Conclusion
DOTA and DOPA improve tumor detection in EAS by increasing Se of structural scans and PPV of detected lesions. The two scans are complementary and should be integral to imaging strategies for EAS. However, DOPA is not currently approved by the Food and Drug Administration for this indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Biomedical and Metabolic Imaging Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Positron Emission Tomography, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Henrik Elenius, Raven McGlotten, Chuong D Hoang, Clara C Chen, Corina Millo, Ahmed M Gharib, Lynnette K Nieman
Förderung
- NIH
- The National Institute of Diabetes, and Digestive and Kidney Diseases
- National Institute of Child Health and Human Development
Zitieren
APA
Elenius, H., McGlotten, R., Hoang, C. D., Chen, C. C., Millo, C., Gharib, A. M., & Nieman, L. K. (2025). Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome. The Journal of Clinical Endocrinology & Metabolism, 110(11), e3794-e3802. https://doi.org/10.1210/clinem/dgaf114
Vancouver
Elenius H, McGlotten R, Hoang CD, Chen CC, Millo C, Gharib AM, et al. Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025;110(11):e3794-e3802. doi:10.1210/clinem/dgaf114
BibTeX
@article{Elenius2025,
author = {Elenius, Henrik and McGlotten, Raven and Hoang, Chuong D and Chen, Clara C and Millo, Corina and Gharib, Ahmed M and Nieman, Lynnette K},
title = {Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {11},
pages = {e3794--e3802},
doi = {10.1210/clinem/dgaf114}
}
EUVIMED